ClinicalTrials.gg
RecruitingNCT05065021Updated Jan 17, 2024

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

A Phase 2 interventional study of Niraparib and Dostarlimab in Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-17.

Sponsored by University Health Network, Toronto · Phase 2, Interventional, and Treatment

How we know · 10 judgments

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies testing niraparib in Ovarian Neoplasms — 9 open to participants now, 15 under way, 2 of them phase 3. niraparib · Ovarian Neoplasms.

Planned enrollment
23rd of 44
40 · median 41
Started
2023
with 3 others
Phase 2
18 of 44
5 open now
Primary completion
2025-06
later than 5 of 14 live
Registered
33rd of 44
by date

Among the 44 studies testing niraparib in Ovarian Neoplasms, this one is the 23rd largest by planned enrollment, is one of 4 that started in 2023, is one of 18 in phase 2, reaches primary completion later than 5 of the 14 other live ones, and was the 33rd registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

9 of the 44 studies testing niraparib in Ovarian Neoplasms are open now, in 10 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About niraparib

niraparib: first FDA approval 2017 (ZEJULA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing niraparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

The purpose of this research study is to see how useful it is to look at biomarkers in the blood and tumor tissue of participants with ovarian, fallopian tube or primary peritoneal cancer who have previously received treatment with a drug called a PARP inhibitor, and using the results to determine the best treatment for these participants. Biomarkers are molecules such as genes (molecules that contain instructions for the development and function of cells in the body) and proteins that may be used to see how well a body responds to certain treatments.

Read the detailed description

Participants who join the study will first have samples of their blood and tumor tissue collected for biomarker testing. The testing will involve a method called "sequencing". This test will look for changes in the genes of your tumor. The results of the testing will be what is called the participant's molecular profile.

All participants will first receive bevacizumab and niraparib for 3 cycles. A cycle will be 21-days in length.

Once the participant's molecular profile has been determined, the study doctor will discuss the results with the participants and they may be referred to a genetic counsellor.

Participants will then be assigned to a study cohort (group) and receive a combination of the study drugs based on the results of their genetic testing:

  • Cohort A: Participants who do not have the required gene changes will be assigned to receive niraparib, bevacizumab, and dostarlimab
  • Cohort B: Participants who have certain gene changes will receive paclitaxel, bevacizumab, and dostarlimab.
  • Cohort C: If the participant and the study doctor think that the participant is benefitting from the combination of bevacizumab and niraparib, or the molecular profile shows that bevacizumab and niraparib is the most suitable, the participant may continue to receive this drug combination.

Participants will receive the study drug combination until disease worsening or they meet the criteria for discontinuation.

03

Conditions studied

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer
  • High Grade Serous Cancer
  • High Grade Endometrioid Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance status 0-2.
  • confirmed ovarian, fallopian tube or primary peritoneal cancer, high grade serous or high grade endometrioid histology subtype.
  • Patients must have disease, either platinum-sensitive, resistant or refractory, with no limit to number of lines of prior systemic therapy.
  • Radiographically documented disease progression within 28 days of registration.
  • Patient must have as per (RECIST) 1.1
  • Progression on any prior Poly (ADP-ribose) polymerase (PARP) inhibitor therapy, with no limit to number of prior lines of PARP inhibitors.
  • Patients must have adequate bone marrow, renal and hepatic function within 7 days of registration
  • (LVEF) > 50% by echocardiograms or multigated acquisition (MUGA) scan within 28 days of registration.
  • Patients are willing to undergo tumor pre-treatment (tissue at the time of progression on PARP inhibitor therapy).
  • Availability of archival tissue (prior to PARP inhibitor therapy) for analysis.
  • Women of must agree to use a highly effective method for study-required period. A negative high sensitive urine or serum pregnancy test within 3 days prior to the initiation of therapy will be required for women of childbearing potential.
  • Patient must agree to not donate blood during the study or for 90 days after the last dose of study treatment.
  • Patient must agree to not breastfeed during the study or for 30 days after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Treatment with an (other than PARP inhibitor) drug within 30 days and treatment with PARP inhibitor within 14 days prior to the first dose of study medication.
  • Major surgery within 4 weeks of registration or ongoing post-surgical complications.
  • Patients with current or are at high-risk of developing fistula, or any other gastrointestinal disorders likely to interfere with absorption of the study medication.
  • Patients with current or history of bowel obstruction within the last 3 months.
  • Untreated unstable brain or .
  • Greater than +1 proteinuria on two consecutive dipsticks within 14 days of registration.
  • Unresolved toxicity of > grade 1 from previous anti-cancer therapy (including radiotherapy).

.History of poorly controlled hypertension or resting blood pressure >140/90 mmHg in the presence or absence of a stable regimen of anti-hypertensive therapy within 7 days of registration.

  • Mean >470 msec in screening within 7 days of registration or history of familial long QT syndrome.
  • Any evidence of severe or uncontrolled diseases such as but not limited to unstable or uncompensated respiratory, cardiac, hepatic, renal disease or psychiatric illness/social situations that would limit compliance with study requirements.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab, paclitaxel, dostarlimab, or niraparib.
  • Patients who have received prior weekly paclitaxel in the recurrent ovarian cancer setting.
  • Patients who have received prior inhibitor for ovarian cancer.
  • Active disease that has required systemic treatment in the past 2 years.
  • History of interstitial lung disease.
  • Patients with myelodysplastic syndrome/acute myeloid leukemia
  • Previous allogenic bone marrow transplant.
  • Immuno-compromised patients, e.g., patients who are known to be serologically positive for (HIV), patients with known active hepatitis (i.e., or C).
  • Patients with significant hemorrhage (>30 mL bleeding/episode in previous 3 months) or hemoptysis (>5 mL fresh blood in previous 4 weeks).
  • Patients who have had recent (within 2 weeks of registration, or until any wound has completely healed) major thoracic or abdominal surgery prior to study start, or a surgical incision that is not fully healed.
  • History of stroke or within six months.
  • Patients that are receiving other anti-cancer therapy (except patient currently progressing on treatment with PARP inhibitor), radiotherapy, biological therapy or other novel agent prior to start of study treatment.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the participant inappropriate for entry into the study.
  • History of other primary second (except for adequately treated cutaneous basal or squamous cell carcinoma or carcinoma in situ) within \< 3 years.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Initial/Cohort C

    Niraparib by mouth (orally), once a day, every day. Bevacizumab, by vein (intravenously), once every 3 weeks for up to 1 year, then every 6 weeks.

    Drug: Niraparib · Drug: Bevacizumab

  • Experimental
    Cohort A

    Niraparib by mouth (orally), once a day, every day. Bevacizumab, by vein (intravenously), once every 3 weeks for up to 1 year, then every 6 weeks. Dostarlimab, by vein (intravenously), once every 3 weeks for 4 doses, then every 6 weeks afterwards.

    Drug: Niraparib · Drug: Dostarlimab · Drug: Bevacizumab

  • Experimental
    Cohort B

    Paclitaxel, by vein (intravenously), once a week. Bevacizumab, by vein (intravenously), once every 3 weeks for up to 1 year, then every 6 weeks. Dostarlimab, by vein (intravenously), once every 3 weeks for 4 doses, then every 6 weeks afterwards.

    Drug: Dostarlimab · Drug: Bevacizumab · Drug: Paclitaxel

Interventions

  • Niraparib works by blocking poly(ADP-ribose) polymerases (PARP) 1 and PARP 2 from working. PARP 1 and PARP 2 are proteins that are involved in cell growth, cell survival, and cell death, including cancer cells. It is believed that blocking PARP1 and PARP 2 from working will slow or stop the growth of cancer cells.

    Also known as: ZEJULA

  • Dostarlimab is a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. A monoclonal antibody is a special kind of antibody that is created in a laboratory that seeks out specific proteins in the body that may be involved in cancers to stop tumor growth. Dostarlimab attaches to PD-1 and inhibits the interaction of PD-L1 and PD-L2 with PD-1.

  • Bevacizumab is a chemotherapy drug commonly used for the treatment of various cancers.

  • Paclitaxel is a chemotherapy drug commonly used for the treatment of various cancers.

06

What researchers measure

Primary outcomes

  1. Percentage of participants that achieve biomarker-guided treatment

    Time frame: 3 years

  2. Response rate percentage

    Time frame: 3 years

Secondary outcomes

  1. Overall response rate for Cohort A

    Time frame: 3 years

  2. Overall response rate for Cohort B

    Time frame: 3 years

  3. Overall response rate for initial cohort/Cohort C

    Time frame: 3 years

  4. Progression-free survival rate for initial cohort/Cohort C

    Time frame: 3 years

  5. Progression-free survival rate for initial cohort/Cohort A

    Time frame: 3 years

  6. Progression-free survival rate for initial cohort/Cohort B

    Time frame: 3 years

  7. CA125 response rate for initial cohort/Cohort C

    Time frame: 3 years

  8. CA125 response rate for Cohort A

    Time frame: 3 years

  9. CA125 response rate for Cohort B

    Time frame: 3 years

  10. Disease control rate for initial cohort/Cohort C

    Time frame: 3 years

  11. Disease control rate for Cohort A

    Time frame: 3 years

  12. Disease control rate for Cohort B

    Time frame: 3 years

  13. Percentage of participants with adverse events in the initial cohort/Cohort C

    Time frame: 3 years

  14. Percentage of participants with adverse events in Cohort A

    Time frame: 3 years

  15. Percentage of participants with adverse events in Cohort B

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Jun 2025, 27 months after the start.

Of 229 non-industry phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 80. This study's planned 27 months is below that.

Counting every sponsor, half of 345 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2021
First posted
Oct 1, 2021
StartActual
Feb 23, 2023
Primary completionEst.
Jun 6, 2025
CompletionEst.
Jun 6, 2025
Last update
Jan 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05065021
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 1, 2021
Start date
Feb 23, 2023
Primary completion
Jun 6, 2025 (estimated)
Completion
Jun 6, 2025 (estimated)
Last update
Jan 17, 2024

Study contacts

Stephanie Lheureux, M.D.
Contact
stephanie.lheureux@uhn.ca
416-946-2818
Stephanie Lheureux, M.D.
principal investigator · Princess Margaret Cancer Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Niraparib · Paclitaxel

Start the discussion